“We are thrilled to partner with Cognome to advance AI and Machine Learning in healthcare,” says Jennifer D’Angelo, NJII’s COO and CEO of HCIS. “By aligning stakeholder initiatives, we can ensure all hospitals and providers benefit from AI-driven innovation, enhancing research, patient care, safety and operations.”  

NJII, an NJIT corporation, is dedicated to accelerating healthcare technology and fostering innovation throughout New Jersey and beyond. Cognome, formed through a joint venture between Montefiore Health System and the University of Texas at Houston, offers advanced AI and Machine Learning models, as well as the first-of-its-kind AI Governance platform, ExplainerAI^TM, purpose-built for healthcare. For over a decade, NJII has been a trusted leader in healthcare technology, data interoperability, and care transformation. NJII aims to drive AI adoption starting with proper governance, model implementation and co-development with our healthcare partners.  

“This partnership aligns with our commitment to accelerate innovation in key sectors such as healthcare,” says Tom Villani, PhD, NJII’s VP of AI and Machine Learning. “All of our AI models integrate seamlessly with EHRs, delivering real-time insights to physicians. The Sepsis reduction model has demonstrated the lowest flag rate in the industry. AutoChart AI reduces manual chart abstraction by over 90%, providing significant ROI through operational efficiencies and prospective attribution.”  

The ExplainerAI^TM platform, built on the NIH AI Governance framework, enhances trustworthiness and transparency while reducing bias through responsible AI models—crucial for clinician adoption. It also aligns with NIST’s AI Risk Management Framework addressing the need for proper privacy, auditability, cybersecurity and compliance for AI models including those from third parties.

“Partnering with NJII combines our 15 years of building proven AI and ML capabilities with their deep knowledge and collaboration throughout NJ’s healthcare ecosystem,” says James Green, Cognome’s CEO. “Size and diversity in patient data are the ‘fuel’ for intelligent, accurate, and responsible AI models.”  

The partnership will bring together healthcare delivery stakeholders including researchers, technology leaders, AI/ML practitioners as well as operational and quality teams to collaborate on high-value use cases. NJII will also provide data science expertise and custom model development services to meet the growing demand for advanced analytics and purpose-built AI solutions.  

To learn more about this partnership, focused on delivering high-value operational and clinical use cases, join our upcoming Webinar: Accelerating AI Adoption in NJ Healthcare: Collaboration & Real-World Impact – on April 29th at 12pm EDT. Register now.  

For more information, visit:

NJII – New Jersey Innovation Institute (NJII) | An NJIT Corporation  

HCIS – Healthcare Innovation Solutions, Inc. (HCIS)  

Cognome – AI-Powered Healthcare and Clinical Decision-Making | Cognome  

About NJII and Healthcare Innovation Solutions (HCIS):  
NJII, a 501c3 non-profit subsidiary of NJIT, turns ideas into workable solutions in healthcare, strategic partnerships, defense, and education. NJII combines NJIT’s resources and strong industry ties to drive innovation that impacts the economy and public welfare. HCIS, a wholly owned subsidiary of NJII, provides quality and performance improvement solutions that help providers succeed with population health and value-based care programs such as MIPS/MVPs, QIP-NJ, TEAM and others.  

About Cognome: With 15+ years of R&D, seven patents, and real-time AI and ML models deployed across 20+ hospitals, Cognome is revolutionizing how healthcare data transforms care delivery, clinical operations, and medical research.  

The post New Jersey Innovation Institute and Cognome Announce Strategic Partnership to Advance AI-Powered Healthcare Solutions appeared first on NJII.

Consider the impact of being able to access a complete patient profile at any point in care. This includes a patient’s most recent blood glucose levels, HbA1c, blood pressure, and even their last eye exam results. These critical numbers are essential for treating and managing diabetes, providing insight into a patient’s condition and progress over time. With interoperability, healthcare providers across a range of specialties—from primary care to endocrinology—can see the same information, which helps eliminate redundant tests, prevents conflicting treatments, and creates a more cohesive care experience. 

For diabetes care, where patients often need to consult multiple specialists, interoperability enables seamless collaboration. When a provider can access recent lab results or consult a patient’s complete medication history, it removes the guesswork from the treatment process. This real-time data access supports healthcare teams in making precise adjustments to treatment plans, and it empowers them to intervene proactively before complications arise. 

Interoperability also brings a new level of responsiveness to diabetes management. Imagine a scenario where a patient with diabetes ends up in the emergency room for a complication. Through an interconnected system, real-time alerts can notify all the patient’s providers of this event, allowing the primary care physician or diabetes specialist to follow up immediately. Timely communication like this is crucial in diabetes care, where swift intervention can prevent further health issues and improve long-term outcomes. 

Beyond individual patient care, the benefits of interoperability extend to public health and population management. When patient data is shared across systems, healthcare organizations and public health officials can identify patterns, such as areas with higher rates of diabetes or clusters of patients with unmanaged blood glucose levels. This broad view allows for targeted community health initiatives, effective allocation of resources, and even policy development aimed at reducing diabetes prevalence. 

For example, data collected through interoperable systems can be invaluable in evaluating the success of prevention programs, such as the National Diabetes Prevention Program (DPP), which promotes lifestyle changes to reduce the risk of type 2 diabetes. Officials can measure the impact of these initiatives, refining their approaches to better serve communities with the highest needs. 

This Diabetes Awareness Month, the message of “knowing your numbers” is more powerful than ever, as interoperability enables those numbers to travel alongside the patient, informing every care decision. For healthcare providers, the benefits of interoperability translate into more comprehensive care delivery, while patients receive continuity and quality of care across their healthcare journey. 

By connecting data across the continuum of care, interoperability enhances every aspect of diabetes management, from timely treatments to informed decision-making, ultimately paving the way for a future where diabetes care is not only more effective but deeply personalized. In essence, interoperability makes it possible to provide smarter, more connected care, improving the lives of people living with diabetes and strengthening the health of communities overall. 

References 

1. Office of the National Coordinator for Health Information Technology (ONC). (2021). The Importance of Interoperability in Healthcare. ONC Health IT 
2. Centers for Disease Control and Prevention (CDC). (2022). Diabetes Data and Statistics. CDC Diabetes 
3. NJII Digital Transformation Advancing Healthcare Technology Digital Transformation 
4. National Diabetes Prevention Program (DPP). (2023). Preventing Type 2 Diabetes: The DPP’s Role in Early Intervention.  National DPP  

The post The Power of Interoperability in Diabetes Patient Care appeared first on NJII.